Genprex, Inc. (GNPX)
1.89
-0.09
(-4.55%)
USD |
NASDAQ |
Oct 23, 11:10
Genprex Enterprise Value : -14.15M for Oct. 22, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 22, 2026 | -14.15M |
| October 21, 2026 | -14.12M |
| October 20, 2026 | -14.08M |
| October 19, 2026 | -14.11M |
| October 16, 2026 | -14.09M |
| October 15, 2026 | -14.00M |
| October 14, 2026 | -13.97M |
| October 13, 2026 | -13.88M |
| October 12, 2026 | -13.79M |
| October 09, 2026 | -13.78M |
| October 08, 2026 | -13.76M |
| October 07, 2026 | -13.83M |
| October 06, 2026 | -13.83M |
| October 05, 2026 | -13.78M |
| October 02, 2026 | -13.82M |
| October 01, 2026 | -13.86M |
| September 30, 2026 | -13.68M |
| September 29, 2026 | -13.71M |
| September 28, 2026 | -13.73M |
| September 25, 2026 | -13.49M |
| September 24, 2026 | -13.37M |
| September 23, 2026 | -13.26M |
| September 22, 2026 | -13.36M |
| September 21, 2026 | -13.39M |
| September 18, 2026 | -13.41M |
| Date | Value |
|---|---|
| September 17, 2026 | -13.40M |
| September 16, 2026 | -13.43M |
| September 15, 2026 | -13.48M |
| September 14, 2026 | -13.41M |
| September 11, 2026 | -13.46M |
| September 10, 2026 | -13.46M |
| September 09, 2026 | -13.42M |
| September 08, 2026 | -13.36M |
| September 04, 2026 | -13.38M |
| September 03, 2026 | -13.42M |
| September 02, 2026 | -13.38M |
| September 01, 2026 | -13.36M |
| August 31, 2026 | -13.28M |
| August 28, 2026 | -13.30M |
| August 27, 2026 | -13.33M |
| August 26, 2026 | -13.14M |
| August 25, 2026 | -13.13M |
| August 24, 2026 | -13.12M |
| August 21, 2026 | -13.15M |
| August 20, 2026 | -13.15M |
| August 19, 2026 | -13.13M |
| August 18, 2026 | -13.15M |
| August 17, 2026 | -12.89M |
| August 14, 2026 | -12.97M |
| August 13, 2026 | -12.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.613B |
| Alnylam Pharmaceuticals, Inc. | 30.07B |
| Anika Therapeutics, Inc. | 269.09M |
| Savara, Inc. | 789.89M |
| Vericel Corp. | 2.131B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.447M |
| Total Expenses (Quarterly) | 4.447M |
| EPS Diluted (Quarterly) | -9.399 |
| Earnings Yield | -8.40K% |
| Normalized Earnings Yield | -8399.88 |